Researchers have now developed a new vaccine, a native outer membrane vesicle (NOMV) vaccine, for meningitis and bloodstream infections caused by ‘meningococcal group B’ bacteria. This will allow younger people to be vaccinated and will address several limitations of the current vaccinations.